;

Auto Summaries - Clinical Trials and Similar Human Studies
Last updated: 2022 Jan 4
Total hit(s): 4360
S.No.
1
34941607
Implementation of an Emergency Department-Embedded Infusion Center for the Administration of Monoclonal Antibody Therapy in Patients With Early COVID-19 Infection
This type of therapy would normally be offered at an outpatient infusion center. These centers often serve persons who are immunocompromised, and introducing COVID-19-positive individuals could threaten the safety of this population. This article describes the deployment of an emergency department-embedded infusion center set up for the purpose of supporting community members and providers electing for this treatment option.
J Infus Nurs
2022 Jan-Feb 01
1
2
34937699
SARS-CoV-2 spreads through cell-to-cell transmission
SARS-CoV-2 is a highly transmissible coronavirus responsible for the global COVID-19 pandemic. Cell-to-cell transmission refractory to inhibition by neutralizing antibody or convalescent sera of patients. Treatment of cocultured cells with endosomal entry inhibitors impairs cellular transmission.
Proc Natl Acad Sci U S A
2022 Jan 4
9.35
2
3
34863618
Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington
Little is known about COVID-19 vaccination intent among people experiencing homelessness. Strong disparities in vaccine intent based on race, education, and prior vaccine history were observed. Increased vaccine intent over the study period was not detected. An intersectional, person-centered approach to addressing health inequities by public health authorities planning vaccination campaigns in shelters is recommended.
Vaccine
2022 Jan 3
3.31
1
4
34875467
Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir's limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed inhibitory activity against SARS-CoV-2 in some studies. We adopted a drug repurposing strategy and further investigated hydroxy chloroquine.
Bioorg Med Chem
2022 Jan 1
1
5
34630624
Epidemic model dynamics and fuzzy neural-network optimal control with impulsive traveling and migrating: Case study of COVID-19 vaccination
Quarantine motions may affect the economic systems and pharmaceutical medications may be recently in the developing phase. Vaccination seems the best hope of the current situation to control COVID-19 epidemics. The theoretical framework of the proposed schemes validates the reduction of symptomatic infectious individuals by using fewer doses of vaccines comparing with the scheduling vaccination.
Biomed Signal Process Control
2022 Jan
3.83
1
6
34901799
Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
Inactivated COVID-19 vaccines are safe and effective in the general population with intact immunity. However, their safety and immunogenicity have not been demonstrated in people living with HIV (PLWH) 42 HIV-1 infected individuals who were stable on combination antiretroviral therapy(cART) and 28 healthy individuals were enrolled in this open-label two-arm non-randomized study at Hubei Provincial Center for Disease Control and Prevention, China.
EClinicalMedicine
2022 Jan
6.68
1
7
34938959
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
The sustainability of vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined. A gradual decline in both NAbs and anti-S-RBD IgGs became evident from 2 weeks to 9 months postvaccination. This finding may reflect a declining degree of immune protection against COVID-19 and advocates for the administration of booster vaccine shots especially in areas with emerging outbreaks.
Hemasphere
2022 Jan
1
8
34926119
COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
SARS-CoV-2 pandemic has endangered world health and the economy. Different companies have started developing potential vaccines using both traditional and nano-based platforms to overcome the pandemic. Oxford-AstraZeneca, Pfizer-BioNTech's BNT162, Moderna's mRNA-1273, Sinovac's CoronaVac, Johnson & Johnson, Sputnik-V, and Sinopharm's vaccine candidates are leading the race. Some EUA vaccines have been reported to induce rare side effects such as blood clots, cardiac injury, anaphylaxis, and some neurological effects.
3 Biotech
2022 Jan
2.27
1
9
34243904
Clinical Management of COVID-19 Patients - An Update
SARS-CoV-2 virus may cause COVID-19 disease, which causes mild-to-moderate disease in 80% of laboratory-confirmed cases. A considerable age-dependent mortality is seen among elderly and other at-risk populations but among young and healthy individuals it is < 0.5%.
Semin Nucl Med
2022 Jan
3
10
34901912
Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany
The adverse drug reaction database of the Paul-Ehrlich Institute was queried for TTS cases following ChAdOx1 nCoV-19 vaccination from February 1, until May 21, 2021. Cerebral venous sinus thrombosis confirmed in 37 (71%) women, 15 (29%) men, median age 460 years (interquartile range 310-603 years) 12 patients died and non-survivors showed lower platelet counts compared to survivors.
Lancet Reg Health Eur
2022 Jan
n/a
2
11
34950394
Cryptococcal Meningoencephalitis During Convalescence From Severe COVID-19 Pneumonia
In this report, a 76-year-old woman survived a bout of respiratory failure from severe COVID-19 pneumonia. Soon after discharge, she developed acute encephalopathy and multifocal ischemic strokes. CSF and blood cultures were positive for Cryptococcus neoformans. Treatment with high-dose steroids and tocilizumab may be predisposing factors.
Neurohospitalist
2022 Jan
2
12
34934447
Therapeutic plasma exchange followed by convalescent plasma transfusion in severe and critically ill COVID-19 patients: A single centre non-randomized controlled trial
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of the study was to determine whether combining TPE with convalescent plasma (CVP) transfusion early in the intensive care unit (ICU) stay improves survival among this heterogeneous population. Survival at 30 days was 47.37% in the TPE CVP group and 26.32% in the control group.
Exp Ther Med
2022 Jan
1.49
1
13
34896578
An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 Neutralizing antibody levels in COVID-19 patients and vaccinees
A specific and sensitive automated chemiluminescent immunoassay (CLIA) was developed. This method can be used for SARS-COV-2 diagnosis, treatment and vaccine evaluation. The effectiveness, protectiveness and durability of vaccine can be evaluated effectively by mathmatical models.
Int J Infect Dis
2021 Dec 9
3.42
1
14
34917247
Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19
N/A
ACS Med Chem Lett
2021 Dec 9
3.75
1
15
34946540
Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment
42 pyrimidonic pharmaceuticals (PPs) inhibitory effect of 42 PPs on the 3-chymotrypsin-like protease of SARS-CoV-2. 11 drugs approved by the US Food and Drug Administration showed an excellent binding affinity to the catalytic residues of 3CL(pro) of His41 and Cys145. Citicoline and uridine triacetate showed free binding energies of -25.53 and -7.07 kcal/mol, respectively. Therefore, I recommend that they be repurposed for the fight against COVID-19, following proper experimental and clinical validation.
Molecules
2021 Dec 9
3.01
1
16
34896122
Comparisons of the immunological landscape of COVID-19 patients based on sex and disease severity by multi-omics analysis
Researchers used analytical framework of 382 transcriptional modules and multi-omics analyses to discriminate COVID-19 patients based on sex and disease severity. Moderate female patients showed a higher adaptive immune response than males matched group. Inflammation modules showed ascending overexpression in male and female patients, while a higher level was observed in severe female patients. Pathways involved in metabolism dysregulation and Hippo signaling were upregulated in females than in male patients.
Chem Biol Interact
2021 Dec 9
3.45
1
17
34945060
Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia
The effects of immunomodulators in patients with Coronavirus Disease 2019 (COVID-19) pneumonia are still unknown. We investigated the cellular inflammatory and molecular changes in response to standard-of-care + pidotimod (PDT) and explored the possible association with blood biomarkers of disease severity.
J Clin Med
2021 Dec 9
6.78
1
18
34880010
Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden
An open randomised controlled trial enrolling patients with COVID-19, who must be SARS-CoV-2 positive in both airway and blood samples. 600 participants will be enrolled to the CP therapy arm and 300 participants to the control arm. The primary endpoint is mortality by day 28 after study inclusion.
BMJ Open
2021 Dec 8
2.49
1
19
34886784
From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine Against COVID-19, Day to Save the Life
COVID-19 is caused by a new strain of coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given the pandemic's high fatality rate and quick expansion, an effective vaccination is urgently needed to keep it under control. More than a dozen vaccines have already been approved around the world, with many more in clinical trials.
Recent Pat Biotechnol
2021 Dec 8
1
20
34920226
Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination
COVID-19 vaccination efficacy depends on serum levels of the neutralizing antibodies (NAs) specific to the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. We developed a novel nanoplasmonic immunosorbent assay (NanoPISA) platform for one-step rapid quantification of NAs in clinical serum samples for high-throughput evaluation of vaccine effectiveness.
Biosens Bioelectron
2021 Dec 8
9.52
1
21
34878955
Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases
Immunosuppressed patients are particularly vulnerable to severe infection from SARS-CoV-2, risking prolonged viremia and symptom duration. The study is one of only few studies on CCP treatment of COVID-19 in hospitalized patients with severe immunosuppression. Prospective, randomized trials are needed to investigate this further.
Infect Dis (Lond)
2021 Dec 8
1.23
1
22
34878625
A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2
A single dose of LY-CovMab was shown to be safe and well tolerated in Chinese healthy adults. The elimination half-life (t(1/2) value did not differ among different dose cohorts and was estimated to be around 28.5 days.
Infect Dis Ther
2021 Dec 8
3.95
1
23
34878902
Analysis of B cell receptor repertoires reveals key signatures of systemic B cell response after SARS-CoV-2 infection
A comprehensive study of the B cell response against SARS-CoV-2 could be significant for understanding the immune response and developing therapeutic antibodies and vaccines. We analyzed the mRNA transcripts of immunoglobulin heavy chain (IgH) repertoires of 24 peripheral blood samples collected between 3 and 111 days after symptom onset from 10 COVID-19 patients. The proportion of low-SHM IgG clones strongly correlated with spike-specific IgG antibody titers.
J Virol
2021 Dec 8
4.16
1
24
34909785
The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders
Postvaccination antibodies are robustly produced by those with inflammatory bowel disease (IBD) even on immune-modifying therapies but are blunted by anti-TNF therapy. In contrast, T-cell response which determines long-term efficacy against disease progression is less well understood. Age, sex and select immunotherapies are associated with the T-Cell clonal response to SARS-CoV-2 vaccines.
medRxiv
2021 Dec 8
Cant find
1
25
34909781
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report
SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. Whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase, which was not present in pre-treatment specimens.
medRxiv
2021 Dec 7
Cant find
1